Genomic mapping identifies mutations in ryr2 and ahnak as associated with favorable outcome in basal-like breast tumors expressing pd1/pd-l1

Cimas, F.J.; Manzano, A.; Baliu-Piqué, M.; García-Gil, E.; Pérez-Segura, P.; Nagy, Á. [Nagy, Ádám (biológia), szerző] Enzimológiai Intézet (TTK); II. Sz. Gyermekgyógyászati Klinika (SE / AOK / K); Bioinformatika Tanszék (SE / AOK / I); Pandiella, A.; Győrffy, B. [Győrffy, Balázs (Onkológia), szerző] II. Sz. Gyermekgyógyászati Klinika (SE / AOK / K); Onkológiai Biomarker Kutatócsoport (Lendület) (HRN TTK / MÉI); Bioinformatika Tanszék (SE / AOK / I); Ocana, A. ✉

Angol nyelvű Szakcikk (Folyóiratcikk) Tudományos
Megjelent: CANCERS 2072-6694 12 (8) Paper: 2243 , 15 p. 2020
  • SJR Scopus - Oncology: Q1
Treatment with anti-PD-L1 antibodies has shown efficacy in basal-like breast cancer. In this context, identification of pre-activated immune tumors is a main goal. Here we explore mutations in PD1 and PD-L1 high-expressing tumors to identify genomic correlates associated with outcome. To do so, RNA-seq and mutation data from 971 breast cancer patients from the TCGA dataset were used to identify most prevalent mutations in patients with high levels of PD1 and PD-L1. Transcriptomic signatures associated with the selected mutations were identified and analyzed in terms of outcome and immune cell infiltration. We identified co-occurrent mutations in RYR2 and AHNAK in 8% and 5% of basal-like tumors respectively, which conferred good prognosis in patients with high expression of PD1 and PD-L1 genes. The transcriptomic signature associated with these mutations, composed of CXCL9, GBP5, C1QA, IL2RG, CSF2RB, IDO1 and LAG3 genes, also conferred good prognosis and correlated with immune infiltrations within the tumors. The joint signature classified patients with favorable relapse-free survival (HR: 0.28; CI: 0.2–0.38; p = 1.7 × 10−16) and overall survival (HR: 0.18; CI: 0.09–0.34; p = 6.8 × 10−9), showing a stronger prediction capacity than previous reported signatures. In conclusion, we describe two novel mutations and their transcriptomic signature, both associated with a favorable outcome and immune infiltrates in PD1 and PD-L1 high-expressing basal-like tumors. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Hivatkozás stílusok: IEEEACMAPAChicagoHarvardCSLMásolásNyomtatás
2024-07-17 20:43